Carbon Monoxide and Fibrin Amyloid Structure Formation

THE CARCO STRESS MODEL: Carbon Monoxide Exposure → Peroxynitrite Formation in Capillaries → Fibrin Amyloid Formation → Microvascular Obstruction → Reduced Mitochondrial Oxygen Availability → Aerobic Energy Production Failure → Systemic Dysfunctions

How Carbon Monoxide Leads to Fibrin Amyloid Formation

Carbon monoxide displaces nitric oxide from platelets, leading to the formation of peroxynitrite. This peroxynitrite directly triggers neutrophils to release neutrophil extracellular traps NETs.  They contain neutrophil DNA together with proteins including myeloperoxidase (MPO) and neutrophil elastase.

Conversion Into Abnormal Amyloid Structures

This sequence places carbon monoxide, heme-associated iron, fibrinogen, activated platelets, and MPO to interact in the same spot.  This direct chemical interaction causes abnormal protein folding to a densely packed amyloid configuration.

Structural Differences From Normal Fibrin Clot

The resulting fibrinaloid structures are physically denser than ordinary physiological fibrin. Fibrin amyloid structures are not normal physiological structures produced during ordinary blood clotting. Normal clotting produces an organized fibrin network to stabilize an injured vessel.

Fibrin Amyloid Structures Resist Normal Breakdown

Resistance to Normal Fibrin Clot Removal

Studies show that persistent fibrin amyloid microclots remain after normal plasma proteins are removed. These abnormal structures are substantially more resistant to physical breakdown than ordinary fibrin clots. The structures remain in the blood circulation even though the body has mechanisms to break down ordinary clots.

Enzyme Access and Abnormally Folded Aggregates

Fibrinogen amyloid structures present the body with a fundamentally altered protein architecture. The material consists of abnormally folded fibrinogen aggregates. This dense structure is poorly accessible to the specific enzymes responsible for normal clot breakdown.

Mechanisms of Persistence

The established finding is that fibrinogen amyloid structures are unusually resistant to degradation. It remains unresolved exactly how much of this persistence results from impaired enzyme access, altered protein structure, or other physical mechanisms.

Accumulation in the Microcirculation

Ongoing Formation and Accumulation

As long as carbon monoxide exposure continues, the body remains trapped in a cycle of ongoing clot formation and incomplete clot removal. Because fibrin amyloid structures are dense and resistant to breakdown, they persist and accumulate within the blood circulation.

Microvascular Obstruction and Oxygen Delivery

When fibrin amyloid structures and activated platelets accumulate in microscopic vessels, they narrow the pathways for red blood cells. As more microvessels become obstructed, red blood cells carrying oxygen can no longer reach all capillaries.

Uneven and Insufficient Tissue Oxygen

This physical obstruction makes oxygen delivery to the surrounding tissues increasingly uneven and insufficient. Some tissue regions receive less oxygen, while others become functionally cut off from their normal oxygen supply.

Occurrence in Chronic and Neurodegenerative Diseases

Long COVID and ME/CFS

Abnormal blood clotting and fibrin amyloid microclots are observed in Long COVID and ME/CFS. Blood samples in both conditions show increased clotting activity and hyperactivated platelets. They also contain amyloid fibrinogen structures that resist normal breakdown.

Alzheimer’s Disease

Studies demonstrate the presence of specific amyloid-fibrinogen complexes in blood plasma and cerebrospinal fluid. The physical presence of these structural complexes serves as a direct biomarker for Alzheimer’s disease.

Fibromyalgia

Studies document physical changes in clotting and fibrin-related processes in people with fibromyalgia. Scientific reviews propose that fibrin amyloid microclots explain how these blood changes directly connect with fibromyalgia symptoms.

Biological Basics for Understanding the Model

How Normal Fibrin Clotting Works

Under normal conditions, fibrinogen is a soluble protein circulating in blood plasma. When a vessel is injured, the coagulation system converts fibrinogen into fibrin. Fibrin forms a branching network that reinforces the platelet clot and temporarily seals the damaged vessel.

The Normal Clot Removal Process

Once tissue repair progresses, the body breaks down the fibrin network. This normal physical process allows the temporary clot to be removed completely. The sequence goes from vessel injury and platelet activation to temporary clot formation and eventual breakdown.

Differences in Fibrin Amyloid Formation

Fibrin amyloid formation differs fundamentally from normal blood clotting. The fibrinogen adopts an abnormal, densely packed amyloid architecture. This solid structure is much more resistant to the body’s ordinary clot-removal mechanisms.

Carbon monoxide initiates direct chemical reactions where peroxynitrite triggers dense, breakdown-resistant fibrin amyloid structures, progressively obstructing blood flow and tissue oxygen delivery.

Sources